Beam Therapeutics Inc
BEAM16.860USD
+0.220+1.32%
Cierre 08/27, 16:00（ET）Cotizaciones retrasadas 15 min
1.70BCap. mercado
PérdidaP/E TTM
Más Datos de Beam Therapeutics Inc Compañía
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Información de la empresa
Símbolo de cotizaciónBEAM
Nombre de la empresaBeam Therapeutics Inc
Fecha de salida a bolsaFeb 06, 2020
Director ejecutivoMr. John M. Evans
Número de empleados483
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 06
Dirección238 Main Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono18573278775
Sitio Webhttps://beamtx.com/
Símbolo de cotizaciónBEAM
Fecha de salida a bolsaFeb 06, 2020
Director ejecutivoMr. John M. Evans
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
7.47M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
12.38%
ARK Investment Management LLC
10.29%
Farallon Capital Management, L.L.C.
9.90%
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
6.64%
Otro
51.21%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
12.38%
ARK Investment Management LLC
10.29%
Farallon Capital Management, L.L.C.
9.90%
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
6.64%
Otro
51.21%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
55.18%
Hedge Fund
20.88%
Investment Advisor/Hedge Fund
19.51%
Venture Capital
4.81%
Research Firm
3.80%
Individual Investor
1.27%
Bank and Trust
0.67%
Pension Fund
0.28%
Family Office
0.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
537
101.17M
100.03%
+11.84M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
2023Q1
583
68.81M
92.54%
-724.80K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
7.60M
7.56%
+4.49M
+144.60%
Mar 31, 2025
ARK Investment Management LLC
8.48M
8.43%
+1.41M
+19.98%
Mar 31, 2025
Farallon Capital Management, L.L.C.
9.93M
9.87%
+1.69M
+20.50%
Mar 31, 2025
The Vanguard Group, Inc.
8.85M
8.8%
+1.24M
+16.36%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.76M
6.72%
+838.01K
+14.15%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
4.27M
4.24%
+309.26K
+7.81%
Mar 31, 2025
ARCH Venture Partners
4.54M
4.51%
--
--
Mar 31, 2025
State Street Global Advisors (US)
3.44M
3.42%
+362.74K
+11.79%
Mar 31, 2025
Bellevue Asset Management AG
2.40M
2.38%
+877.81K
+57.82%
Mar 31, 2025
Kynam Capital Management LP
2.52M
2.5%
+762.01K
+43.39%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
3.21%
Global X Genomics & Biotechnology ETF
2.09%
WisdomTree BioRevolution Fund
1.74%
ARK Innovation ETF
1.58%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Franklin Genomic Advancements ETF
0.79%
SPDR S&P Biotech ETF
0.61%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
iShares Health Innovation Active ETF
0.2%
Invesco Nasdaq Biotechnology ETF
0.19%
Ver más
ARK Genomic Revolution ETF
Proporción3.21%
Global X Genomics & Biotechnology ETF
Proporción2.09%
WisdomTree BioRevolution Fund
Proporción1.74%
ARK Innovation ETF
Proporción1.58%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.88%
Franklin Genomic Advancements ETF
Proporción0.79%
SPDR S&P Biotech ETF
Proporción0.61%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.39%
iShares Health Innovation Active ETF
Proporción0.2%
Invesco Nasdaq Biotechnology ETF
Proporción0.19%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
